Taylor, Cottrill, Erickson & Associates, Inc. Repligen Corp Transaction History

Taylor, Cottrill, Erickson & Associates, Inc.

$359 Million
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 May 03, 2022	SELL	$161.19 - $257.96 $128,952 - $206,367	-800 Closed	0 $0
Q3 2021 Oct 15, 2021	BUY	$194.77 - $324.21 $155,816 - $259,367	800 New	800 $231,000

Others Institutions Holding RGEN

# of Institutions

488

Shares Held

54.2M

Call Options Held

341K

Put Options Held

235K

Black Rock Inc. New York, NY

7.57M
Shares

$1.17 Billion
0.02% of portfolio
Price T Rowe Associates Inc Baltimore, MD

6.39M
Shares

$990 Million
0.11% of portfolio
Vanguard Group Inc Valley Forge, PA

5.04M
Shares

$781 Million
0.01% of portfolio
State Street Corp Boston, MA

1.62M
Shares

$251 Million
0.01% of portfolio
Champlain Investment Partners, LLC Burlington, VT

1.42M
Shares

$220 Million
1.34% of portfolio

View Full List

About REPLIGEN CORP

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $8.59B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

More about RGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Taylor, Cottrill, Erickson & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Taylor, Cottrill, Erickson & Associates, Inc. with notifications on news.

Account